Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 and first-half 2026 operating results and business highlights released for periods ended June 30, 2026.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 operating results and business highlights released for periods ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the substantive financial and operating details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.